Navigation Links
Drug in New Hepatitis C Clinical Trial
Date:8/24/2007

BRISBANE, Australia, Aug. 24 /PRNewswire/ -- Physicians at Southern Health have started a phase IIa clinical trial designed to test the efficacy of a new strategy for defeating hepatitis C viral infection, one of the toughest infectious diseases in the modern world.

Implicit Bioscience's drug, oglufanide disodium, which works as a regulator of the body's immune response, is being given by intranasal administration to patients with chronic hepatitis C viral infection.

"The drugs currently in use fail to control this disease in about one half of all patients," said Dr Ian Frazer, Implicit's Chief Scientific Officer. "So there is a compelling need for new and better therapies, and we hope that oglufanide disodium may control or reverse the suppression of the immune system which the hepatitis virus uses to defeat our normally healthy defenses."

Dr Frazer is well known as the co-inventor of the recently approved vaccine for papillomavirus, which is designed to prevent cervical cancer.

Dr William Sievert, who is the Principal Investigator for the trial, welcomed the opportunity to study the action of oglufanide disodium in his busy liver diseases clinic at the Monash Medical Centre, which is part of the Southern Health network. "It is an important opportunity for patients to be involved in a new trial such as this, in which new treatment prospects are explored."

Oglufanide disodium was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before being acquired by the privately-owned Brisbane biotech company Implicit Bioscience Pty Ltd in 2005.

The phase IIa trial of intranasal oglufanide disodium will complement the ongoing phase Ib study of subcutaneously administered drug at the Princess Alexandra Hospital in Brisbane.

Oglufanide disodium regulates the body's innate immune response to defeat invading germs and cancer cells. The drug is also under development by Implicit as a biodefense therapy and for ovarian cancer.


'/>"/>
SOURCE Implicit Bioscience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
4. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
5. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
7. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
8. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
9. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
10. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
11. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... New York , February 5, 2016 ... new Transparency Market Research report states that the global ... in 2014 and is predicted to reach US$185.9 bn ... CAGR of 6.50% from 2014 to 2020. The title ... (Branded/Generic/Over-the-counter, Chemical/Biological, Captive/Contract Manufactured, by Geography, and by Therapeutic ...
(Date:2/5/2016)... , February 5, 2016 ... new market research report "Fetal (Labor & Delivery) and ... Antepartum), Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, CPAP, ... by MarketsandMarkets, This report studies the global market over ... is estimated at USD 6.28 Billion in 2015 and ...
(Date:2/5/2016)... France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for the ... age and sex in these markets. GD epidemiology report is written and ... quality, transparent and market-driven, providing expert analysis of disease trends in the ... , Italy , Spain , UK, ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association ... restaurants, launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 ... ALS and related diseases that severely limit strength and mobility. , Now ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... is poised to once again host, Swirl, A Wine Tasting Event at the ...
(Date:2/5/2016)... ... , ... Give To Cure today announced that it is working ... To Cure’s campaign that is crowdfunding clinical trials to help find cures faster for ... a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. ...
(Date:2/5/2016)... ... ... Stuart Bentkover, MD, FACS is thrilled to announce the arrival ... tattoo removal today, Dr. Bentkover is the only doctor in Central Massachusetts to offer ... been approved by the Food and Drug Administration (FDA) as a safe and efficient ...
(Date:2/5/2016)... ... ... California Mobile Kitchens , a company that designs ... kitchen model, featuring customizable stainless steel interiors and a new, 26-foot unit. , ... in the U.S. Many of their units can be seen at sporting events, ...
Breaking Medicine News(10 mins):